BioArctic Information

BioArctic AB (publ) is a Swedish research-based biopharma company focusing on treatments that can delay or stop the progression of neurodegenerative diseases. BioArctic invented the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. In addition, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer and Parkinson projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential. GDPR information: https://www.bioarctic.se/en/social-media-privacy-policy/